Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017153465) METHODS FOR PROGNOSIS AND TREATMENT OF COLORECTAL CANCER
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1 . A method for making a prognosis of colorectal cancer in a patient suffering from colorectal cancer, the method comprising steps of:

- determining PKC Beta II levels in a biological sample of colorectal cancer epithelial tissue from the patient;

determining PKC Beta II levels in a biological sample of normal distant epithelial tissue from the patient; and

comparing determined levels of PKC Beta II in the cancer and normal distant epithelial tissue samples to make the prognosis.

2. The method as claimed in claim 1 wherein the prognosis is poor where determined levels of PKC Beta II in the normal distant epithelial tissue sample are lower than determined levels of PKC Beta II in the cancer sample or where a percentage difference between determined levels of PKC Beta II in the normal distant epithelial tissue sample and determined levels of PKC Beta II in the cancer sample is 10% or less.

3. The method as claimed in claim 2 wherein a poor prognosis predicts a disease free survival period of less than ten years.

4. The method as claimed in claim 1 wherein the prognosis is good where determined levels of PKC Beta II in the normal distant epithelial tissue sample are higher than determined levels of PKC Beta II in the cancer sample and a percentage difference therebetween is more than 10%.

5. The method as claimed in claim 4 wherein a good prognosis predicts a disease free survival period of more than ten years.

6. The method as claimed in any one of claims 1 -5 wherein the sample comprising normal distant epithelial tissue is a sample taken 5-15cm (+/- 2cm) from the colorectal cancer tissue in the patient.

7. The method as claimed in claim 6 wherein the sample comprising normal distant epithelial tissue is a sample taken 8-12cm from the colorectal cancer tissue in the patient.

8. The method as claimed in any one of claims 1 -7 wherein the method comprises determining PKC Beta II gene expression levels.

9. The method as claimed in any one of claims 1 -7 wherein the method comprises determining PKC Beta II protein levels.

10. A method for determining a suitable treatment for a patient suffering from colorectal cancer, the method comprising steps of:

determining PKC Beta II levels in a biological sample of colorectal cancer tissue from the patient;

- determining PKC Beta II levels in a biological sample of normal tissue from the patient; and

comparing determined levels of PKC Beta II in the cancer and normal tissue samples to determine a suitable treatment.

1 1 . The method as claimed in claim 10 wherein if determined levels of PKC Beta II in the normal tissue sample are higher than determined levels of PKC Beta II in the colorectal cancer sample and a percentage difference therebetween is more than 10%, a suitable treatment comprises upregulating expression and/or activity of PKC Beta II.

12. The method as claimed in claim 10 or 1 1 wherein the sample of colorectal cancer tissue is epithelial tissue, stromal tissue or a mixture thereof and the sample of normal tissue is epithelial tissue, stromal tissue or a mixture thereof.

13. The method as claimed in any one of claims 10-12 wherein the method comprises determining PKC Beta II gene expression levels.

14. The method as claimed in any one of claims 10-12 wherein the method comprises determining PKC Beta II protein levels.

15. PKC Beta II or a drug which upregulates expression and/or activity of PKC Beta II for use in treatment of colorectal cancer in a subject in need thereof.